Amy E DeZern1, Donna Dorr, Robert A Brodsky. 1. Division of Hematology, Department of Medicine, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
Abstract
BACKGROUND: Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal, hematopoietic stem cell disorder that manifests with hemolytic anemia and bone marrow failure. Eculizumab has been shown to improve anemia, decrease intravascular hemolysis, and reduce the risk of thrombosis. DESIGN AND METHODS: This is a retrospective, single-center study of patients treated with eculizumab and categorized according to response criteria. Complete response (CR) was defined as transfusion independence with normal hemoglobin for age/sex, absence of symptoms, and lactate dehydrogenase <1.5 times the upper limit of normal. A good partial response (GPR) was defined as decreased transfusions from pretreatment and lactate dehydrogenase <1.5 upper limit of normal without thrombosis. These patients did not achieve normal hemoglobins for age and sex. A suboptimal response was defined as unchanged transfusion needs and persistent of symptoms. RESULTS: Thirty patients with PNH clones were treated with eculizumab and classified as complete responders (four patients), good partial responders (16), and suboptimal responders (10) over 863 patient-months of treatment. Complete responders had a decrease in red cell clone size, while good partial responders had an increase. Thirteen patients treated did not meet inclusion criteria for the clinical trials of eculizumab due to lack of transfusions or thrombocytopenia; eight had at least a GPR. CONCLUSIONS: Eculizumab is efficacious in patients with PNH, but responses can vary and may depend on underlying marrow failure, underlying inflammatory conditions and red cell clone size following treatment. Normalization of hemoglobin with decrease in red cell clone size may predict CR.
BACKGROUND:Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal, hematopoietic stem cell disorder that manifests with hemolytic anemia and bone marrow failure. Eculizumab has been shown to improve anemia, decrease intravascular hemolysis, and reduce the risk of thrombosis. DESIGN AND METHODS: This is a retrospective, single-center study of patients treated with eculizumab and categorized according to response criteria. Complete response (CR) was defined as transfusion independence with normal hemoglobin for age/sex, absence of symptoms, and lactate dehydrogenase <1.5 times the upper limit of normal. A good partial response (GPR) was defined as decreased transfusions from pretreatment and lactate dehydrogenase <1.5 upper limit of normal without thrombosis. These patients did not achieve normal hemoglobins for age and sex. A suboptimal response was defined as unchanged transfusion needs and persistent of symptoms. RESULTS: Thirty patients with PNH clones were treated with eculizumab and classified as complete responders (four patients), good partial responders (16), and suboptimal responders (10) over 863 patient-months of treatment. Complete responders had a decrease in red cell clone size, while good partial responders had an increase. Thirteen patients treated did not meet inclusion criteria for the clinical trials of eculizumab due to lack of transfusions or thrombocytopenia; eight had at least a GPR. CONCLUSIONS:Eculizumab is efficacious in patients with PNH, but responses can vary and may depend on underlying marrow failure, underlying inflammatory conditions and red cell clone size following treatment. Normalization of hemoglobin with decrease in red cell clone size may predict CR.
Authors: Michael J Borowitz; Fiona E Craig; Joseph A Digiuseppe; Andrea J Illingworth; Wendell Rosse; D Robert Sutherland; Carl T Wittwer; Stephen J Richards Journal: Cytometry B Clin Cytom Date: 2010-07 Impact factor: 3.058
Authors: Masha Fridkis-Hareli; Michael Storek; Istvan Mazsaroff; Antonio M Risitano; Ante S Lundberg; Christopher J Horvath; V Michael Holers Journal: Blood Date: 2011-08-22 Impact factor: 22.113
Authors: Anita Hill; Russell P Rother; Louise Arnold; Richard Kelly; Matthew J Cullen; Stephen J Richards; Peter Hillmen Journal: Haematologica Date: 2010-02-09 Impact factor: 9.941
Authors: Peter Hillmen; Neal S Young; Jörg Schubert; Robert A Brodsky; Gerard Socié; Petra Muus; Alexander Röth; Jeffrey Szer; Modupe O Elebute; Ryotaro Nakamura; Paul Browne; Antonio M Risitano; Anita Hill; Hubert Schrezenmeier; Chieh-Lin Fu; Jaroslaw Maciejewski; Scott A Rollins; Christopher F Mojcik; Russell P Rother; Lucio Luzzatto Journal: N Engl J Med Date: 2006-09-21 Impact factor: 91.245
Authors: Richard J Kelly; Anita Hill; Louise M Arnold; Gemma L Brooksbank; Stephen J Richards; Matthew Cullen; Lindsay D Mitchell; Dena R Cohen; Walter M Gregory; Peter Hillmen Journal: Blood Date: 2011-04-01 Impact factor: 22.113
Authors: Antonio M Risitano; Rosario Notaro; Ludovica Marando; Bianca Serio; Danilo Ranaldi; Elisa Seneca; Patrizia Ricci; Fiorella Alfinito; Andrea Camera; Giacomo Gianfaldoni; Angela Amendola; Carla Boschetti; Eros Di Bona; Giorgio Fratellanza; Filippo Barbano; Francesco Rodeghiero; Alberto Zanella; Anna Paola Iori; Carmine Selleri; Lucio Luzzatto; Bruno Rotoli Journal: Blood Date: 2009-01-29 Impact factor: 22.113
Authors: Russell P Rother; Scott A Rollins; Christopher F Mojcik; Robert A Brodsky; Leonard Bell Journal: Nat Biotechnol Date: 2007-11 Impact factor: 54.908
Authors: C Wehling; O Amon; M Bommer; B Hoppe; K Kentouche; G Schalk; R Weimer; M Wiesener; B Hohenstein; B Tönshoff; R Büscher; H Fehrenbach; Ö-N Gök; M Kirschfink Journal: Clin Exp Immunol Date: 2016-11-25 Impact factor: 4.330
Authors: Amy E DeZern; Marc Uknis; Xuan Yuan; Galina L Mukhina; Juan Varela; JoAnne Saye; Jeffrey Pu; Robert A Brodsky Journal: Exp Hematol Date: 2014-07-14 Impact factor: 3.084